Atomoxetine; Reboxetine; Viloxazine/Monoamine Oxidase Inhib Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both medicines effect chemical levels in the brain.
What might happen:
Taking these medicines together can result in serious side effects, including high fever, muscle stiffness, muscle spasms, agitation, confusion, coma, and death.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) right away about taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Strattera (atomoxetine hydrochloride) US prescribing information. Eli Lilly and Company January, 2022.
- 2.Edronax (reboxetine mesylate) Australian prescribing information. Pfizer Australia Pty Ltd. November 8, 2022.
- 3.Qelbree (viloxazine) US prescribing information. Catalent Pharma Solutions, LLC April, 2021.
- 4.Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007 Nov;152(6):946-51.
- 5.Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000 Jun;56(3):247-50.
- 6.Fisar Z, Hroudova J, Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett 2010; 31(5):645-56.
- 7.Aggarwal A, Kulkarni G, Jahan S. Potential serious adverse interactions between linezolid and atomoxetine. J Child Adolesc Psychopharmacol 2012 Oct;22(5):405.
- 8.Surmaitis RM, Nappe TM, Cook MD. Serotonin syndrome associated with therapeutic metaxalone in a patient with cirrhosis. Am J Emerg Med 2016 Feb;34(2):346.e5-6.
- 9.Skelaxin (metaxalone) US prescribing information. Pfizer Laboratories Div Pfizer Inc. January, 2024.
- 10.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.